Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says

MT Newswires Live

Feb 13

Neurocrine Biosciences' (NBIX) Ingrezza product remains its "core value driver," supporting long-term growth assumptions for the company, Morgan Stanley said in a Thursday note.

The company reported fiscal Q4 adjusted net income late Wednesday of $1.88 per diluted share, up from $1.69 a year earlier, as revenue rose to $805.5 million from $627.7 million. Neurocrine Biosciences also said it expects Ingrezza's 2026 net product sales to range from $2.7 billion to $2.8 billion.

Morgan Stanley said Ingrezza's Q4 sales of $657 million indicated "durable" demand, with a double-digit volume growth, even after nine years since its launch. The firm also noted the company's Crenessity product, which outperformed fresh from its launch with a $135 million sales in Q4.

The investment firm said it raised its 2026 non-GAAP EPS forecast for the company to $7.48 from $7.29.

Morgan Stanley lowered its price target on Neurocrine Biosciences to $173 from $175, with an equal-weight rating.

Price: 125.00, Change: -12.44, Percent Change: -9.05

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611973661"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611973661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611973661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 00:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611973661","market":"sh","top_or_hot":-1,"title":"Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> Neurocrine Biosciences' (NBIX) Ingrezza product remains its \"core value driver,\" supporting long-term growth assumptions for the company, Morgan Stanley said in a Thursday note.</p><p>The company reported fiscal Q4 adjusted net income late Wednesday of $1.88 per diluted share, up from $1.69 a year earlier, as revenue rose to $805.5 million from $627.7 million. Neurocrine Biosciences also said it expects Ingrezza's 2026 net product sales to range from $2.7 billion to $2.8 billion.</p><p>Morgan Stanley said Ingrezza's Q4 sales of $657 million indicated \"durable\" demand, with a double-digit volume growth, even after nine years since its launch. The firm also noted the company's Crenessity product, which outperformed fresh from its launch with a $135 million sales in Q4.</p><p>The investment firm said it raised its 2026 non-GAAP EPS forecast for the company to $7.48 from $7.29.</p><p>Morgan Stanley lowered its price target on Neurocrine Biosciences to $173 from $175, with an equal-weight rating.</p><p>Price: 125.00, Change: -12.44, Percent Change: -9.05</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-13 00:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Neurocrine Biosciences' (NBIX) Ingrezza product remains its \"core value driver,\" supporting long-term growth assumptions for the company, Morgan Stanley said in a Thursday note.</p><p>The company reported fiscal Q4 adjusted net income late Wednesday of $1.88 per diluted share, up from $1.69 a year earlier, as revenue rose to $805.5 million from $627.7 million. Neurocrine Biosciences also said it expects Ingrezza's 2026 net product sales to range from $2.7 billion to $2.8 billion.</p><p>Morgan Stanley said Ingrezza's Q4 sales of $657 million indicated \"durable\" demand, with a double-digit volume growth, even after nine years since its launch. The firm also noted the company's Crenessity product, which outperformed fresh from its launch with a $135 million sales in Q4.</p><p>The investment firm said it raised its 2026 non-GAAP EPS forecast for the company to $7.48 from $7.29.</p><p>Morgan Stanley lowered its price target on Neurocrine Biosciences to $173 from $175, with an equal-weight rating.</p><p>Price: 125.00, Change: -12.44, Percent Change: -9.05</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0006306889.USD","symbol_name":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2611973661","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611973661","pubTimestamp":1770912491,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurocrine Biosciences'  Ingrezza product remains its \"core value driver,\" supporting long-term growth assumptions for the company, Morgan Stanley said in a Thursday note.The company reported fiscal Q4 adjusted net income late Wednesday of $1.88 per diluted share, up from $1.69 a year earlier, as revenue rose to $805.5 million from $627.7 million. Neurocrine Biosciences also said it expects Ingrezza's 2026 net product sales to range from $2.7 billion to $2.8 billion.Morgan Stanley said Ingrezza's Q4 sales of $657 million indicated \"durable\" demand, with a double-digit volume growth, even after nine years since its launch. The firm also noted the company's Crenessity product, which outperformed fresh from its launch with a $135 million sales in Q4.The investment firm said it raised its 2026 non-GAAP EPS forecast for the company to $7.48 from $7.29.Morgan Stanley lowered its price target on Neurocrine Biosciences to $173 from $175, with an equal-weight rating.Price: 125.00, Change: -12.4","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0557290698.USD":"施罗德环球可持续增长基金","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4581":"高盛持仓","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0971096721.USD":"富达环球金融服务 A","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1548497426.USD":"安联环球人工智能AT Acc","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4139":"生物科技","NBIX":"神经分泌生物科学","LU0106831901.USD":"贝莱德世界金融基金A2","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4504":"桥水持仓","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1732800096.USD":"摩根大通环球收益基金A (irc)"},"translate_title":"摩根士丹利表示，Neurocrine Biosciences的Ingrezza仍然是“核心价值驱动力”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1.5},"content_text":"Neurocrine Biosciences' (NBIX) Ingrezza product remains its \"core value driver,\" supporting long-term growth assumptions for the company, Morgan Stanley said in a Thursday note.The company reported fiscal Q4 adjusted net income late Wednesday of $1.88 per diluted share, up from $1.69 a year earlier, as revenue rose to $805.5 million from $627.7 million. Neurocrine Biosciences also said it expects Ingrezza's 2026 net product sales to range from $2.7 billion to $2.8 billion.Morgan Stanley said Ingrezza's Q4 sales of $657 million indicated \"durable\" demand, with a double-digit volume growth, even after nine years since its launch. The firm also noted the company's Crenessity product, which outperformed fresh from its launch with a $135 million sales in Q4.The investment firm said it raised its 2026 non-GAAP EPS forecast for the company to $7.48 from $7.29.Morgan Stanley lowered its price target on Neurocrine Biosciences to $173 from $175, with an equal-weight rating.Price: 125.00, Change: -12.44, Percent Change: -9.05","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}